Literature DB >> 15076229

Extracellular nitric oxide release mediates soluble guanylate cyclase-independent vasodilator action of spermine NONOate: comparison with other nitric oxide donors in isolated rat femoral arteries.

M R Miller1, K Okubo, M J Roseberry, D J Webb, I L Megson.   

Abstract

Nitric oxide (NO) and NO donors exhibit actions that are not entirely mediated by soluble guanylate cyclase (sGC). The site of NO release may influence the involvement of sGC-independent effects. Here we use spermine NONOate (SPER/NO) to release NO extracellularly, compared with other NO donors. Isolated rat femoral arteries were perfused luminally and perfusion pressure monitored. Vessels were contracted with phenylephrine (2-14 microM) in the presence of an NO synthase inhibitor (N(omega)-nitro-L-arginine methyl ester; 20 microM). Vasodilator responses to NO donors were assessed before and after perfusion of an sGC inhibitor (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; ODQ; 20 microM), NO scavengers (hemoglobin; Hb & hydroquinone; HQ), and a superoxide generator (duroquinone; DQ). ODQ (20 microM) abolished the vasodilator responses to glyceryl trinitrate (10(-8) - 10(-3) M), and sodium nitroprusside (10(-8) - 10(-4) M), which release NO intracellularly. ODQ (20 microM) attenuated, but failed to abolish, the vasodilator responses to SPER/NO (10(-6) - 10(-3) M). ODQ abolished responses to S-nitrosoglutathione and S-nitroso-N-valeryl-D-penicillamine (10(-8) - 10(-4) M), but a small residual vasodilatation remained in response to 10(-3) M. In the presence of ODQ, the remaining vasodilatation to SPER/NO was all but abolished by scavengers of extracellular NO (Hb; 10 microM, HQ; 100 microM). Superoxide generation (DQ; 100 microM) also attenuated ODQ-resistant vasodilatation. The data suggest that, in rat femoral arteries, NO donors that are capable of releasing extracellular NO cause vasodilatation that is only partially mediated by sGC. Lack of augmentation of sGC-independent effects by superoxide suggests that they are not mediated by peroxynitrite.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15076229     DOI: 10.1097/00005344-200403000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

2.  Augmented dilation to nitric oxide in uterine arteries from rats with type 2 diabetes: implications for vascular adaptations to pregnancy.

Authors:  Styliani Goulopoulou; Johanna L Hannan; Takayuki Matsumoto; Adviye Ergul; R Clinton Webb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-12-13       Impact factor: 4.733

3.  A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations.

Authors:  Michael S Crane; Adriano G Rossi; Ian L Megson
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

4.  Two N-(2-phenylethyl)nitroaniline derivatives as precursors for slow and sustained nitric oxide release agents.

Authors:  Alec R Badour; John A Wisniewski; Dillip K Mohanty; Philip J Squattrito
Journal:  Acta Crystallogr C Struct Chem       Date:  2016-04-13       Impact factor: 1.172

5.  The NO donor sodium nitroprusside: evaluation of skeletal muscle vascular and metabolic dysfunction.

Authors:  Daniel M Hirai; Steven W Copp; Scott K Ferguson; Clark T Holdsworth; Timothy I Musch; David C Poole
Journal:  Microvasc Res       Date:  2012-11-19       Impact factor: 3.514

6.  Direct impairment of vascular function by diesel exhaust particulate through reduced bioavailability of endothelium-derived nitric oxide induced by superoxide free radicals.

Authors:  Mark R Miller; Stephen J Borthwick; Catherine A Shaw; Steven G McLean; Daniel McClure; Nicholas L Mills; Rodger Duffin; Ken Donaldson; Ian L Megson; Patrick W F Hadoke; David E Newby
Journal:  Environ Health Perspect       Date:  2008-12-17       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.